Advances in research on long non-coding RNA in drug resistance of colorectal cancer

doi:10.12092/j.issn.1009-2501.2020.07.012

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2020, Vol. 25 ›› Issue (7): 796-802.doi: 10.12092/j.issn.1009-2501.2020.07.012

Previous Articles Next Articles

Advances in research on long non-coding RNA in drug resistance of colorectal cancer

WANG Ziyuan^1,2,3, SUN Mingyu^2,3

¹ Department of Pathology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; ²Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; ³Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Received:2020-04-28 Revised:2020-06-29 Online:2020-07-26 Published:2020-07-31

Abstract

Abstract: Colorectal cancer is the third most prevalent cancer in the world. Surgical resection is the preferred method for the treatment of colorectal cancer, assisted by chemotherapy, targeted therapy and other methods to reduce recurrence and metastasis. However, drug resistance is an important factor in postoperative recurrence and death. Long non-coding RNA (lncRNA) has been found to be involved in drug resistance of colorectal cancer. Therefore, it is of great significance to study the mechanism of lncRNA regulating drug resistance in colorectal cancer. This paper reviewed the progress of lncRNA in drug resistance of colorectal cancer.

Key words: long non-coding RNA, colorectal cancer, drug resistance

CLC Number:

R735.3

WANG Ziyuan, SUN Mingyu. Advances in research on long non-coding RNA in drug resistance of colorectal cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 796-802.

[1]	SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun. Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.
[2]	WEI Zhenzhen, SUI Hua, JIANG Yulang, SUN Mingyu, YAN Huaru, WANG Ziyuan. Research on the molecular mechanism of Zuo Jin Wan combined with cetuximab inducing ferroptosis in KRAS mutant colorectal cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 130-137.
[3]	ZHOU Guangchen, LIU Yixi, ZHENG Yun. Colorectal cancer and microRNA: research progress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 575-587.
[4]	LI Yanyan, FANG Xiaojie, YIN Xin, SUN Xi, RAO Chunhui. circZNF124 regulates the proliferation, migration and invasion of colorectal cancer SW620 cells by targeting miR-4262 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1231-1239.
[5]	LU Qiong, ZHU Haihong, QI Tingting, LI Guohua, TENG Xinqi, QU Qiang, QU Jian. OCTN2 gene polymorphisms affect the chemotherapeutic sensitivity of oxaliplatin in colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 401-407.
[6]	JIN Le, JIANG Duochen, CHEN Hongxiao, LIU Su, CHEN Zhaolin, JU Jing. Quercetin reverses adriamycin resistance by activating GSK-3β/β-catenin pathways through GAS5 in breast cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1344-1351.
[7]	SONG Dandan, CHEN Xueyuan, CHEN Ruiqi, LI Hanqiao, WU Tian. Research status of long non-coding RNA MALAT1 in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 49-57.
[8]	WANG Xianghai, XING Min, LYU Tangfeng, LIU Hongbing, SONG Yong. Effects of knocking down long intergenic non-coding RNA 00467 on the prognosis of patients with lung adenocarcinoma and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 841-849.
[9]	ZHANG Dezhi, LIU Meng, ZHU Shaogong, LIU Guiju, JI Jie. Efficacy and safety of XELOX therapy in comparison with capecitabine monotherapy in adjuvant chemotherapy for elderly patients with colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 926-936.
[10]	HOU Bin, HUANG Weiping, YIN Zhongpu, HU Shousen. lncRNA PCAT19 inhibits the proliferation and invasion of nasopharyngeal carcinoma cells by adsorbing miR-142-5p and regulating the expression of ING3 gene [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 721-727.
[11]	SHI Lili, LIU Xingan, SHAN Guoyong. Efficacy and safety of apatinib in the further line treatment for patients with advanced colorectal cancer failed after standard therapy and the preliminary analysis of efficacy predictors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1388-1394.
[12]	LI Rongzhen, MEI Jiazhuan, XIA Yunzhan, JI Jie. Prognostic factors and safety study of R0 resection colorectal cancer patients received capecitabine based adjuvant chemotherapy in real world [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 704-711.
[13]	QIAO Dawei, LI Yufang, XIAO Yun, JIANG Lishuang, BO Ping. Research progress of Scutellaria barbata against colorectal cancer and its metastasis mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 332-336.
[14]	BAI Yan, ZHENG Xiaoyong, YANG Yage, FANG Lifeng. Influence of programmed death-ligand 1 genetic variation on the clinical outcomes of postoperative CRC patients received 5-FU based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 180-187.
[15]	LI Xiaojie,ZHANG Shengwei,WANG Huasheng,WANG Dong, MEI Jiazhuan, DENG Yewei. Effects of polymorphism of vascular endothelial growth factor A on the prognosis of colorectal cancer patients received fluorouracil based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 900-904.

Advances in research on long non-coding RNA in drug resistance of colorectal cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments